By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Osiris Therapeutics, Inc. 

7015 Albert Einstein Drive

Columbia  Maryland  21046  U.S.A.
Phone: 443-545-1800 Fax: 443-545-1701


SEARCH JOBS
Founded in 1992, Osiris Therapeutics, Inc. is the leader in adult stem cell therapy for tissue regeneration, using its proprietary mesenchymal stem cell (MSC) and universal MSC technologies. These "off-the-shelf" MSCs are isolated from bone marrow of unrelated donors and used in recipients without immune suppression, representing a viable business strategy for the commercialization of stem cell therapies. The Company's current focus includes the use of universal MSCs for bone marrow transplantation support in hematological malignancies, cardiac repair after acute myocardial infarction and congestive heart failure, and regeneration of meniscus post-meniscectomy following knee injury.

The Company's core assets include:
  • our MSC "superplatform" technology applicable to a multitude of potential indications via a single manufacturing process:
  • 37 issued U.S. patents, including the composition of matter patent for MSCs, allowed in the U.S. and EU plus over 150 additional patents pending worldwide:
  • a closed manufacturing system, which proves efficient from a regulatory, cost, space and reproducibility (regardless of indication) perspective:
  • a new, seasoned management team: and
  • an unrelenting product focus.

    Osiris' competitive advantages include:
  • its clear leadership in stem cell therapy as represented by development progress, first-to-clinic status and intellectual property portfolio:
  • universal MSC donor technology with its "off-the-shelf", cryopreserved products, ready for acute or chronic use, relegating potential autologous or allogeneic-matched cell therapies non-competitive relative to efficiency, use and costs: and
  • the lack of real or perceived issues which surround embryonic stem cells including uncontrolled cell growth and differentiation and political and/or ethical controversies.

    The Company is vertically integrated through research, development, manufacturing, QA/QC, regulatory, pre-clinical and clinical development. These operations are located in a single facility on the north shore of the harbor in downtown Baltimore with access to 118,000 square feet. Due to manufacturing efficiencies, this should provide adequate space for the next five years or more. Osiris currently employs approximately 80 people, including 20 MD/PhDs.

    Last Updated: 05-09-03

    Key Statistics


    Email: Osiris@Osiris.com
    Ownership: Public

    Web Site: Osiris
    Employees: 80
    Symbol: OSIR
     









  • Company News
    Osiris (OSIR) Names Former AstraZeneca PLC (AZN) Exec As New CEO 6/26/2017 7:49:20 AM
    Aziyo Biologics Banks Some Cash And Former Osiris (OSIR) Exec As Its New CEO 6/15/2017 7:16:03 AM
    Osiris (OSIR) Appoints David White To Its Board Of Directors 6/1/2017 12:38:55 PM
    Osiris (OSIR) To Present 29 Advanced Clinical And Scientific Abstracts, Including A Late-Breaking Abstract On Its New Ambient Viable Tissue Preservation Technology 4/5/2017 11:31:22 AM
    Osiris (OSIR) Announces Change In Its Board Of Directors 4/3/2017 2:09:53 PM
    Osiris (OSIR) Launches Prestige Lyotechnology, A Novel Method For Ambient Storage Of Living Cells And Tissues 3/31/2017 10:45:50 AM
    Osiris (OSIR) Completes Restatement of 2014 Financial Statements 3/28/2017 11:30:47 AM
    Osiris (OSIR) Receives Notice Of Delisting From NASDAQ 3/13/2017 10:11:14 AM
    Osiris (OSIR) Appoints Uwe Sommer And Thomas Knapp To Its Board Of Directors 2/13/2017 8:22:01 AM
    Osiris (OSIR) Announced A Comparative Effectiveness Study On The Use Of Two Human Placental Membranes In Wound Management Is Available Electronically In A Peer-Reviewed Journal 1/20/2017 7:19:12 AM
    12345678910...
    //-->